bluuebunny/crossref_metadata_2025_split huggingface dataset:
Treatment combined with bone marrow transplantation for advanced neuroblastoma: An analysis of patients who were pretreated intensively with the protocol of the study group of Japan
Authors: Ohnuma Naomi , Takahashi Hideyo , Kaneko Michio , Uchino Jun‐Ichi , Takeda Takeo , Iwafuchi Makoto , Ohhira Mutsuro , Nishihira Hirokazu , Mugishima Hideo , Yokoyama Jotaro , Okada Akira , Nagahara Noboru , Taguchi Nobuyuki , Tsuchida Yoshiaki 
Published: February 2007

AbstractOne hundred and ten patients with advanced neuroblastoma were treated with the protocol of the Study Group of Japan between January 1985 and March 1991. Patients received six cyclic courses of regimen A1, consisting of cyclophosphamide (1,200 mg/m2), vincristine (1.5 mg/m2), tetrahydropyranyl adriamycin (40 mg/m2), and cisplatin (90 mg/m2). Primary tumors and regional lymph node metastases were removed some time during the first six cycles of regimen A1. After six cycles of A1, the patients were divided into three groups. Patients in group 1 received alternating treatment with regimen B (cyclophosphamide and ACNU) and intensified A1, and those in group 2 were treated with alternating administration of regimen C (cyclophosphamide and DTIC) and intensified A1. Patients in group 3 were treated with supralethal therapy and bone marrow transplantation (BMT). Event‐free survival rates at five years were 38.8% in the chemotherapy group (groups 1 and 2) and 50.0% in the transplant group (group 3).Because of the study design that was not in truly randomized fashion and because of the small number of patients in each risk group, it is indicated, though not concluded, that the transplant group had a better prognosis than the chemotherapy group in the cases with stage III disease or with amplified N‐myc oncogene, based on the statistical calculations. Differences in survival rates for patients who underwent BMT when complete remission (CR) was achieved and for those who achieved CR but who did not undergo marrow transplant were statistically insignificant.BMT‐related death occurred in 3 of 31 cases (9.7%) undergoing marrow transplant, and the causes of the death included hemorrhagic pneumonia, myocardial disturbance and hemorrhagic uremia. © 1995 Wi1ey‐Liss Inc.
Unusual secondary tumors after childhood lymphoid malignancy
Authors: Aricò Maurizio , Bossi Grazia , Cecchetto Giovanni , Dall'Igna Patrizia , Viganò Claudia 
Published: February 2007

AbstractSecond malignant neoplasms (SMN) in individuals who survived childhood cancer have been reported with increasing frequency during the last decades. The overall probability of developing second malignancy for children treated for cancer was estimated at about 2–5% at 25 years. In children, the tumors most often associated with the development of SMN are retinoblastoma and Hodgkin's disease.We report two cases of unusual second tumors in two patients cured of lymphoid malignancy: one boy cured of acute lymphoblastic leukemia developed mediastinal ganglioneuroma nine years later and one girl had gastric carcinoma seven years after Hodgkin's disease. Both developed a tumor in nonirradiated areas.Gastric carcinoma and ganglioneuroma are not reported as recurrent SMN in survivors after childhood cancer, with one single case of gastric carcinoma and one of ganglioneuroblastoma having been reported as second tumor in survivors after childhood cancer. © 1995 Wi1ey‐Liss Inc.
Cytomegalovirus‐associated stage 4S neuroblastoma relapsed stage 4
Authors: Nigro Giovanni , Schiavetti Amalia , Booth James C. , Clerico Anna , Dominici Carlo , Krzysztofiak Andrzej , Castello Manuel 
Published: February 2007

AbstractNeuroblastoma is one of the most frequent solid tumors in childhood, rarely recurrent after five years from diagnosis. Cytomegalovirus (CMV), a major pathogen causing congenital birth defects and severe opportunistic diseases, has been shown to have teratogenic, immunodepressive and oncogenic properties.The case of a girl with stage 45 neuroblastoma diagnosed at three months and relapsed as stage 4 five years later is reported. In both circumstances, active CMV infection was revealed by positive CMV‐specific IgM and IgA antibodies, CMV‐DNAemia and CMV culture.At three months, the patient presented with subcutaneous nodules, hepatosplenomegaly and increased aminotransferase levels, and the opsoclonus‐myoclonus syndrome. Mental retardation developed later on. At 5 years, relapsed neuroblastoma was preceded by a mononucleosis‐like syndrome concomitant with active CMV infection and decreased levels of immune cells and natural killer activity.Clinical, virologic, and immunologic findings suggest an immune‐mediated pathogenic role for CMV in this tumor. © 1995 Wi1ey‐Liss Inc.
Primary Hodgkin's disease of the bone
Authors: Fried Geta , Ben Arieh Yehudith , Haim Nissim , Dale Janet , Stein Moshe 
Published: February 2007

AbstractA primary extranodal presentation occurs in less than 0.25% of patients with Hodgkin's disease (HD) and we describe the primary clinicopathologic findings in a rare case of a 21‐year‐old female with primary bony involvement of Hodgkin's disease.The patient presented with microcytic, hypochromic anemia and shoulder pain. The diagnosis of HD (lymphocyte depleted type) was made by biopsy taken from a lytic lesion in the lateral third of the clavicle. Staging work‐up revealed an additional lesion in the ilium, but there was no evidence of lymph node involvement. MOPP/ABV (nitrogen mustard, Oncovin, procarbazine, prednisone/adriamycin, bleomycin, and vinblastine) chemotherapy resulted in complete response lasting, to date, 36 months.To the best of our knowledge, this is only the second reported case of disseminated primary Hodgkin's disease of the bone and all have had a favourable response to combination chemotherapy. A review of the literature is also presented. © 1995 Wi1ey‐Liss Inc.
Reversible thrombocytopenia with levamisole
Authors: Winquist Eric W. , Lassam Norman J. 
Published: February 2007

AbstractLevamisole is an immunomodulatory agent which is used in the adjuvant therapy of certain malignancies. Agranulocytosis is the most commonly reported hematologic side effect associated with this drug. We report here a patient who developed thrombocytopenia nearly 2 years after starting adjuvant levamisole therapy for malignant melanoma. In this case, thrombocytopenia was shown to be levamisole‐related by re‐challenge with the drug. Levamisole‐induced thrombocytopenia (LIT) has been rarely diagnosed, but may be seen more frequently as increasing numbers of patients receive adjuvant therapy for colon cancer and melanoma. © 1995 Wi1ey‐Liss Inc.
Genetic predisposition and cyclophosphamide treatment in a girl with bladder carcinoma?
Authors: Kenet G. , Mandel M. , Mor Y. , Toren A. , Jonas P. , Kende G. , Rechavi G. , Neumann Y. 
Published: February 2007

AbstractTransitional cell carcinoma of the bladder rarely occurs in young female patients. We present a case of bladder carcinoma which appeared after treatment with cyclophosphamide, in a 14‐year‐old girl genetically predisposed to bladder cancer. © 1995 Wi1ey‐Liss Inc.
Wilms' tumor: Cure of malignant pleural effusion exclusively with chemotherapy
Authors: Canpolat Cengiz , Jaffe Norman 
Published: February 2007

AbstractA malignant pleural effusion was diagnosed by thoracentesis in a 12‐year‐old patient with an established diagnosis of Wilms' tumor. He was treated with chemotherapy and achieved a reduction in the size of the primary tumor and resolution of the effusion. The primary tumor was then resected and chemotherapy continued for a total of 18 months. At the request of the parents, radiation therapy to the thorax was withheld. The patient has remained free of disease for the past 8 years. © 1995 Wi1ey‐Liss Inc.
Childhood NHL in Switzerland: Incidence and Survival of 120 Study and 42 Non‐Study Patients
Authors: Wagner H. P. , Dingeldein‐Bettler I. , Berchthold W. , Lüthy A. Ridolfi , Hirt A. , Plüss H. J. , Beck D. , Wyss M. , Signer E. , Imbach P. , Feldges A. , Bleher E. A. , Plaschkes J. , Briner J. , Leibundgut K. , Von Der Weid N. 
Published: February 2007

AbstractBased on the Swiss Pediatric Oncology Group (SPOG) cancer registry data during 1981–1991, a high average incidence of 8 new NHL per million children younger than 15 years per year was found. Of 162 children with NHL registered in 1976–1991, 120 were study patients, i.e., officially registered and treated according to SPOG or Pediatric Oncology Group (POG) protocols, while 42 were non‐study patients, i.e., patients not officially enrolled on protocols.Overall, 91 of 120 (76%) study patients remained alive. Seventy‐nine study patients were treated according to older SPOG protocols, and 53 (67%) of these survived, while 38 of 41 (93%) study patients treated according to newer POG protocols remained alive (P = 0.0068). Only 22 (52%) of the 42 non‐study patients survived (P = 0.0001). There was no improvement if the survival of non‐study patients before and since 1986 was compared. Population‐based treatment results in Switzerland were similar to those in the United Kingdom. They provided an important base for the development of future treatment strategies. © 1995 Wiley‐Liss, Inc.
Non‐11p Constitutional Chromosome Abnormalities in Wilms' Tumor Patients
Authors: Olson Jane M. , Hamilton Anne , Breslow Norman E. 
Published: February 2007

AbstractThe incidence in Wilms' tumor patients of constitutional chromosome defects other than those involving the short arm of chromosome 11 was examined using data on 5,854 patients registered in the National Wilms Tumor Study. Trisomy 18 and Turner syndromes were found to occur at higher rates than expected based on chromosome surveys of newborns. Four patients were reported to have trisomy 18; all of these patients were over 5 years of age at the time of diagnosis of Wilms' tumor and none survived longer than six months. Four patients were reported to have Turner syndrome; these patients are currently doing well and have all survived at least 3 years following diagnosis. Two of the Turner patients and one of the trisomy 18 patients had horseshoe kidneys; we speculate that this renal anomaly may contribute to the higher rates of tumor in these patients. No clear pattern was found among patients with other chromosome defects, although two patients had defects involving 2q37. © 1995 Wi1ey‐Liss, Inc.
Malignant Melanocytic Lesions of Unknown Primary Site in Children and Adolescents
Authors: Pappo Alberto S. , Kuttesch John F. , Kaste Sue C. , Parham David M. , Rao Bhaskar N. , Pratt Charles B. 
Published: February 2007

AbstractBackground. Metastatic melanoma with an unidentified primary site represents 4% of all newly diagnosed cases of malignant melanoma in adults. Little is known of the incidence and clinicopathologic features of this clinical entity in the pediatric population.Methods. We reviewed all previously diagnosed cases of malignant melanoma in children and adolescents (<21 years) who were treated at our institution and identified three patients who presented with metastatic melanocytic lesions with an unidentified primary site.Results. This clinical presentation accounted for 9% of all malignant melanocytic lesions treated at our center over a 20‐year period. The clinicopathologic features were similar to those seen in adults. Two patients died of progressive disease within two years of presentation; the third is alive and disease‐free 18 years post‐diagnosis.Conclusions. Although uncommon in the pediatric population, malignant melanoma should be considered in the differential diagnosis of poorly differentiated disseminated malignancy that involves lymph nodes or viscera with no identifiable primary tumor. © 1995 Wi1ey‐Liss, Inc.
Long‐Term Follow‐Up of Stage III Testicular Carcinoma Treated With Mithramycin (Plicamycin)
Authors: Kennedy B. J. , Torkelson Jane L. 
Published: February 2007

AbstractIn 1965 we reported mithramycin (plicamycin) to produce objective regression in 7 of 12 patients with advanced testicular carcinoma. Between 1963 and 1975 mithramycin was administered to 62 patients with advanced testicular carcinoma as the initial chemotherapy and to 30 patients who failed to respond to prior chemotherapies. There were 13 complete regressions (23%) in 56 patients who as initial chemotherapy received more than one course of mithramycin. The median follow‐up is 23 years with 10 patients still alive. A partial regression occurred in 11 (18%), all of whom are dead. Of 30 patients receiving mithramycin after prior chemotherapies, none had a complete regression, 5 had a partial regression, and all are dead. Of 13 patients undergoing complete regression, 85% never had a recurrence of testicular carcinoma. The median follow‐up of 23 years implies that these patients are cured. © 1995 Wi1ey‐Liss, Inc.
Unusual Cutaneous Toxicity Following Treatment With Dactinomycin: A Report of Two Cases
Authors: Kanwar Vikramjit S. , Gajjar Amar , Ribeiro Raul C. , Bowman Laura , Parham David M. , Jenkins Jesse J. 
Published: February 2007

AbstractDactinomycin‐induced cutaneous toxicity is rare in pediatric patients not receiving radiation therapy. We describe dactinomycin‐related lesions in the axilla, groin, and central line exit site of two children treated for rhabdomyosarcoma, neither of whom had received radiation treatment. One patient was initially treated with systemic antifungal therapy, and developed recurrent lesions on reexposure to the drug. The other was noted to have mild, diffuse hyperpigmentation. Skin biopsies revealed interface dermatitis with syringometaplasia in both cases. Both children recovered uneventfully within 4 weeks. Recognition of unusual rashes with a characteristic distribution in patients receiving dactinomycin should aid in diagnosis, and help avoid unnecessary therapeutic procedures. © 1995 Wi1ey‐Liss, Inc.
Secretion of a Large Molecular‐Weight Form of Insulin‐Like Growth Factor by a Primary Renal Tumor
Authors: Korn Elizabeth , van Hoff Jack , Buckley Patrick , Daughaday William H. , Carpenter Thomas O. 
Published: February 2007

AbstractA 5‐year‐old boy with an abdominal mass was found to have a primary renal tumor of poorly identifiable histology. Prior to resection of the tumor, the patient exhibited several episodes of biochemical hypoglycemia. The hypoglycemia did not recur after operation. Analysis of tumor tissue and of pre‐ and post‐operative sera by column chromatography showed elevated insulin‐like growth factor II (IGF‐II) levels in the tumor; an abnormal large‐molecular weight precursor form of IGF‐II (pro‐IGF‐II) comprised 53% of total IGF‐II in the tumor and 42% in preoperative serum. No pro‐IGF‐II was found in the serum 6 weeks post‐operatively. Abnormal IGF‐II secreted by the tumor may have mediated the hypoglycemia seen prior to tumor resection. This pediatric renal tumor is the first to our knowledge for which an association of non‐islet cell tumor‐related hypoglycemia and elevated tumor IGF‐II content has been described. © 1995 Wi1ey‐Liss, Inc.
Recombinant erythropoietin in acute chemotherapy‐induced anemia of children with cancer
Authors: Beck Maja Nenadov , Beck Daniel 
Published: February 2007

AbstractChemotherapy‐induced anemia in children with cancer is usually of acute onset. To investigate an alternate treatment to transfusion (Tx), we undertook a phase I‐II clinical trial of daily administrations of recombinant erythropoietin (rHuEPO). Patients with a hemoglobin (Hgb) value <75 g/l were treated for 14 days in cohorts of 3 at escalating daily doses of 25, 50, 70, 80, 90, and 100 U/kg respectively. The maximum‐tolerated dose was not encountered. Of 18 courses given to 15 children aged 0.5–18 years, 7 (39%) were associated with increased or stable Hgb levels (courses without Tx), while 11 (61%) were terminated by a Tx, without evidence of a dose‐response relationship. Changes in mean Hgb levels and absolute reticulocyte counts were paralleled by those of mean white blood cell, platelet, and absolute neutrophil counts during the first 7 days and when the end‐points of the study were reached. Numbers of circulating burst‐forming units‐erythroid remained low throughout courses without Tx. No cumulative increase of serially determined serum EPO levels was observed and serum ferritin levels were elevated in both groups of courses.We conclude that daily administrations of rHuEPO were safe but ineffective in our trial. Recovery of chemotherapy‐induced myelosuppression appeared to be the rate‐limiting factor for the outcome, without evidence of an enhanced stimulation of erythropoiesis. The lack of a proliferative response of specific progenitor cells suggested a mechanism of transient primary resistance to rHuEPO. © 1995 Wiley‐Liss, Inc.
Lack of efficacy of postoperative chemotherapy and delayed radiation in very young children with pineoblastoma
Authors: Duffner Patricia K. , Cohen Michael E. , Sanford Robert A. , Horowitz Marc E. , Krischer Jeffrey P. , Burger Peter C. , Friedman Henry S. , Kun Larry E. 
Published: February 2007

AbstractEleven infants with pineoblastomas were treated with prolonged postoperative chemotherapy in an attempt to delay radiation and reduce neurotoxicity. These infants were part of the Pediatric Oncology Group infant brain tumor study but the outcome of infants with pineoblastomas was not previously reported. Ages ranged from 1 month to 35 months, with eight of 11 ≦ 12 months at diagnosis. Four had + cytology and three had + myelograms at diagnosis. The majority had partial surgical resection (25–75% reduction in tumor) and 10 had shunts. Chemotherapy consisted of two 28‐day cycles of cyclophosphamide plus vincristine, followed by one 28‐day cycle of cisplatin plus etoposide. Craniospinal radiation was planned following completion of either 2 years of chemotherapy (children less than 24 months at diagnosis) or following one year (children 24–36 months at diagnosis). Neuroimaging results following two cycles of cyclophosphamide and vincristine were one partial response, five stable disease, and five progressive disease. There were no responders in the leptomeninges. All children ultimately failed chemotherapy (2 months–11 months). Nine failed in the primary site. Of those eight children in whom a metastatic workup was performed at time of progression, all had evidence of leptomeningeal disease. Six received radiation following failure on chemotherapy. All failed either in the primary site, leptomeninges or extraneurally (peritoneal cavity). All children died. Survival following diagnosis ranged from 4 months to 13 months. This chemotherapy regimen was neither effective in controlling tumor in the primary site nor in treating or preventing leptomeningeal spread. © 1995 Wiley‐Liss, Inc.
Incidence of childhood acute lymphoblastic leukemia (ALL) and population‐based treatment results in Switzerland: Experiences with 507 study and 149 nonstudy patients
Authors: Stupnicki A. , von der Weid N. , Imbach P. , Arnet B. , Berchtold W. , Delaleu B. , Hirt A. , Pluess H. J. , Beck D. , Wyss M. , Luethy A. Ridolfi , Feldges A. , Signer E. , Morin A. M. , Caflisch U. , Leibundgut K. , Frey E. , Kuechler H. , Baumgartner C. , Bleher E. A. , Angst R. , Blauenstein U. , Nobile L. , Vischer D. , Wagner H. P. 
Published: February 2007

AbstractOf 656 patients with ALL (all types) diagnosed in Switzerland during 4 consecutive 4‐year periods (1976–1979, 1980–1983, 1984–1987, 1988–1991), 507 were officially registered on protocols (“study” patients) while 149 were not (“nonstudy” patients). The mean incidence of 3.8/100,000 children <15 years/year is higher than reported for other Western countries. Evidence is presented suggesting that the 656 patients represent only approximately 90% of all children with ALL residing in Switzerland, indicating that the true incidence of ALL might even be higher. The fraction of “nonstudy” patients fell from 40% (1976–1979) to 15% (1984–1987). The rate of survival at 4 years of all patients with ALL (“study” and “nonstudy”) increased by 17% during the three consecutive periods 1976–1979, 1980–1983, and 1984–1987. As expected, a higher increase (20%) was observed in “study” patients and a statistically nonsignificant lower one (10%) in “nonstudy” patients. © 1995 Wiley‐Liss, Inc.
Vincristine neuropathy in type I and type II charcot‐marie‐tooth disease (hereditary motor sensory neuropathy)
Authors: Igarashi Masanori , Thompson Elizabeth I. , Rivera Gaston K. 
Published: February 2007

AbstractA patient with Ewing's sarcoma and demyelinating type Charcot‐Marie‐Tooth disease (CMT) developed severe neuropathy after receiving a total vincristine dose of 6 mg. Recovery was slow and incomplete. A second patient with axonal type CMT developed moderate neuropathy but tolerated extended vincristine administration and recovered quickly. Possible underlying neuropathy should be excluded before vincristine treatment is begun by careful examination including inspection of the feet, followed by electrophysiologic studies as indicated. In demyelinating CMT, vincristine should be avoided; in axonal form cautious use may be considered. © 1995 Wiley‐Liss, Inc.
Successful treatment of invasive aspergillosis complicating prolonged treatment‐related neutropenia in acute myelogenous leukemia with amphotericin B lipid complex
Authors: Hospenthal Duane R. , Byrd John C. , Weiss Raymond B. 
Published: February 2007

AbstractHerein we report the successful treatment of invasive aspergillosis with the liposomal amphotericin B (AMB) formulation, Amphotericin B Lipid Complex (ABLC™). This investigational compound was employed in a 50‐year‐old patient with acute myelomonocytic leukemia complicated by prolonged, treatment‐induced granulocytopenia and documented Aspergillus flavus sinusitis with signs of disseminated aspergillosis. The patient demonstrated radiographic signs of pulmonary aspergillosis and biochemical signs of hepatic involvement that were resistant to a 23 day course of conventional AMB (Fungizone®) therapy. Following therapy with ABLC™ her fever abated, her chest X‐ray findings improved, and her hepatic function tests improved with eventual resolution. © 1995 Wiley‐Liss, Inc.
Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International society of paediatric oncology (SIOP) and the (German) society of paediatric oncology (GPO): SIOP II
Authors: Bailey C. C. , Gnekow A. , Wellek S. , Jones M. , Round C. , Brown J. , Phillips A. , Neidhardt M. K. 
Published: February 2007

AbstractIn a multicentre randomised clinical trial 364 children with biopsy proven medulloblastoma were randomly assigned to receive or not pre‐radiotherapy chemotherapy. Children with total or subtotal removal of the tumour, no evidence of invasive brain stem involvement, and no evidence of metastatic disease either within or without the cranium were designated “low risk”, those with gross residual tumour, evidence of invasive brain stem involvement or metastases in the central nervous system were designated “high risk”. All children were prescribed 55 Gy to the tumour bearing area. “Low risk” children could be randomised to “standard” radiotherapy 35 Gy to the craniospinal axis or “reduced” dose 25 Gy to the craniospinal axis. Chemotherapy consisted of vincristine, procarbazine, and methotrexate given in a 6‐week module before radiotherapy, and for “high risk” children, vincristine and CCNU given after radiotherapy. No benefit for the receipt of pre‐radiotherapy chemotherapy could be demonstrated for any group. In addition, a negative interaction was observed between the receipt of the chemotherapy and reduced dose radiotherapy with a particularly poor outcome being observed in this group of children. © 1995 Wiley‐Liss, Inc.